MetLife Valuation

Is MWZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MWZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MWZ (€77.72) is trading below our estimate of fair value (€143.76)

Significantly Below Fair Value: MWZ is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for MWZ?

Key metric: As MWZ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for MWZ. This is calculated by dividing MWZ's market cap by their current earnings.
What is MWZ's PE Ratio?
PE Ratio15.6x
EarningsUS$3.56b
Market CapUS$55.47b

Price to Earnings Ratio vs Peers

How does MWZ's PE Ratio compare to its peers?

The above table shows the PE ratio for MWZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average15.5x
MUV2 Münchener Rückversicherungs-Gesellschaft in München
11.4x2.9%€65.1b
WUW Wüstenrot & Württembergische
25.3x34.6%€1.1b
HNR1 Hannover Rück
13.1x5.7%€29.5b
ALV Allianz
12x6.4%€113.7b
MWZ MetLife
15.8x14.0%€55.5b

Price-To-Earnings vs Peers: MWZ is expensive based on its Price-To-Earnings Ratio (15.8x) compared to the peer average (15.5x).


Price to Earnings Ratio vs Industry

How does MWZ's PE Ratio compare vs other companies in the European Insurance Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
MWZ 15.6xIndustry Avg. 11.9xNo. of Companies14PE0816243240+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: MWZ is expensive based on its Price-To-Earnings Ratio (15.8x) compared to the European Insurance industry average (11.9x).


Price to Earnings Ratio vs Fair Ratio

What is MWZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MWZ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.6x
Fair PE Ratio11.8x

Price-To-Earnings vs Fair Ratio: MWZ is expensive based on its Price-To-Earnings Ratio (15.8x) compared to the estimated Fair Price-To-Earnings Ratio (11.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MWZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€77.72
€89.29
+14.9%
10.0%€98.42€65.61n/a13
Dec ’25€83.17
€87.45
+5.1%
9.6%€96.40€64.91n/a13
Nov ’25€72.07
€82.04
+13.8%
8.6%€90.10€62.52n/a13
Oct ’25€73.31
€76.81
+4.8%
7.8%€85.98€60.90n/a13
Sep ’25€69.83
€74.91
+7.3%
7.2%€85.78€60.76n/a12
Aug ’25€70.01
€77.37
+10.5%
8.6%€88.96€61.16n/a13
Jul ’25€64.68
€76.65
+18.5%
8.9%€92.51€61.67n/a13
Jun ’25€65.04
€76.49
+17.6%
9.1%€91.89€61.26n/a13
May ’25€66.79
€77.46
+16.0%
10.8%€97.87€62.11n/a14
Apr ’25€68.54
€73.58
+7.3%
8.0%€81.42€61.06n/a14
Mar ’25€64.03
€73.58
+14.9%
8.0%€81.42€61.06n/a14
Feb ’25€59.95
€72.51
+20.9%
8.4%€80.96€57.96n/a15
Jan ’25€59.31
€70.83
+19.4%
7.9%€78.89€57.79n/a15
Dec ’24€57.86
€70.40
+21.7%
8.6%€79.28€58.08€83.1715
Nov ’24€56.60
€72.31
+27.8%
8.6%€80.09€59.36€72.0714
Oct ’24€59.39
€72.45
+22.0%
8.7%€79.87€59.20€73.3114
Sep ’24€59.41
€70.45
+18.6%
10.9%€78.68€53.69€69.8314
Aug ’24€57.14
€66.30
+16.0%
11.6%€75.60€51.59€70.0114
Jul ’24€51.63
€67.81
+31.3%
10.7%€78.04€53.25€64.6814
Jun ’24€46.73
€70.38
+50.6%
11.4%€80.47€56.14€65.0414
May ’24€55.45
€69.27
+24.9%
10.1%€78.39€54.69€66.7916
Apr ’24€52.98
€74.51
+40.6%
10.1%€83.95€55.97€68.5416
Mar ’24€66.84
€75.08
+12.3%
7.2%€82.47€57.73€64.0316
Feb ’24€66.04
€75.64
+14.5%
7.6%€85.65€58.02€59.9516
Jan ’24€67.37
€76.63
+13.7%
6.8%€82.58€59.80€59.3115
Dec ’23€72.97
€78.61
+7.7%
7.0%€84.43€61.14€57.8615

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 22:03
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MetLife, Inc. is covered by 36 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jacob KilsteinArgus Research Company
John HeagertyAtlantic Equities LLP
Ishan MajumdarBaptista Research